Lilly Employer Connect aims to make obesity treatments more predictable for employers while lowering costs for workers ...

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.

GLP-1 weight loss drugs are increasingly popular as a treatment for obesity. But a lot of employer-sponsored health plans won ...

Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after ...

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

Eli Lilly and Co. (LLY) on Monday announced a new version of its blockbuster weight-loss drug Zepbound, available in a ...

Eli Lilly is going beyond its efforts to sell its obesity drug Zepbound directly to patients, and is now trying to target ...

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now.

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...